About six months into the pandemic and
about 130 days until the U.S. presidential election, COVID-19 vaccines
are moving ahead at record speeds. Now, a group of analysts predicts “at
least one” vaccine will be approved before November 3.
Jefferies healthcare strategist Jared Holz told MarketWatch
that “perhaps multiple vaccines” could get FDA authorizations “early in
the fourth quarter and quell fears of a second wave of COVID-19.”
The team cited several reasons why an
approval, or emergency use authorization, may come before the November
election. For one, Trump could push the FDA behind the scenes to issue
an approval or emergency authorization. Moderna and AstraZeneca, two
vaccine front-runners, have already told the analysts an approval could
happen on that timeline, according to the report.
Meanwhile, a vaccine approval
might lift the entire industry, rather than just one or two
companies, Holz told the publication. If the industry delivers a
successful shot, it’d be seen as saving the day amid the pandemic, and
that would lift sentiment around all of biopharma. With that lift,
there’d be less political pressure to take on drug pricing.
The analysts at Jefferies aren’t the
only market watchers who believe vaccines could be approved before the
election. In a New York Times op-ed earlier
this month, University of Pennsylvania professors Ezekiel Emanuel and
Paul Offit warned about a possible “October surprise” in the form of a
COVID-19 vaccine approval on political grounds.
FDA commissioner Stephen Hahn, though, said his agency won’t be pressured to approve a shot for political reasons. He told The
Guardian that “science and data—not politics—has and will always guide
our decision-making, including our work related to vaccines.”
Several vaccines, including those from
Moderna and AstraZeneca, are slated for late-stage tests this summer,
The Wall Street Journal has reported. Worldwide, about 140 COVID-19
vaccines are in development, and 13 are in human testing, according to
the World Health Organization.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.